Skip to main content

From the understanding of KRAS-RAF membrane dynamics to new therapeutic strategies in cancer

Project description

KRAS cell membrane dynamic and novel anticancer strategies

The RAS/MAPK pathway integrates signals from a diverse range of stimuli to control cellular homeostasis. It is frequently deregulated in human diseases, including cancer. The GTPase KRAS is part of the RAS/MAPK pathway, and its mutations are implicated in oncogenesis. The overarching goal of the EU-funded KARMA project is the characterisation in vitro and in vivo of the KRAS protein complex and its function concerning human diseases. The project will capitalise on the researcher's discovery that dimerization drives the function of oncogenic KRAS. During the project, the tumour suppressor effect of wild-type KRAS protomers in oncogenic KRAS-driven complexes will be studied, and the therapeutic impact of the complex disruption will be determined.

Host institution

UNIVERSITA DEGLI STUDI DI TORINO
Net EU contribution
€ 1 996 853,00
Address
Via Giuseppe Verdi 8
10124 Torino
Italy

See on map

Region
Nord-Ovest Piemonte Torino
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Beneficiaries (1)

UNIVERSITA DEGLI STUDI DI TORINO
Italy
Net EU contribution
€ 1 996 853,00
Address
Via Giuseppe Verdi 8
10124 Torino

See on map

Region
Nord-Ovest Piemonte Torino
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00